Lineage Cell Therapeutics
LCTX
LCTX
127 hedge funds and large institutions have $49.7M invested in Lineage Cell Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.72% less ownership
Funds ownership: 48.6% → 47.89% (-0.72%)
8% less capital invested
Capital invested by funds: $53.8M → $49.7M (-$4.15M)
Holders
127
Holding in Top 10
2
Calls
$133K
Puts
$1K
Top Buyers
| 1 | +$3.57M | |
| 2 | +$994K | |
| 3 | +$614K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$359K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$238K |
Top Sellers
| 1 | -$3.64M | |
| 2 | -$1.98M | |
| 3 | -$519K | |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$268K |
| 5 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
-$194K |
